The MyoKardia Crew Is Back, and Wall Street Just Handed Them $400 Million

Three Drugs, Three Diseases Nobody Can Treat Yet

Kardigan isn't chasing obesity or cancer, the two hottest areas in biotech right now. Instead, it's targeting three cardiovascular conditions where no approved therapies currently exist. That's a bold bet, but it's also a wide-open market with zero competition.

The pipeline breaks down like this:

Danicamtiv is a direct myosin activator being tested in a Phase 2b/3 trial called KINSHIP-DCM. It targets genetic dilated cardiomyopathy, a condition where inherited mutations cause the heart muscle to weaken and stretch. Think of the heart as a rubber band that's lost its snap; danicamtiv aims to restore the muscle's ability to contract.

Ataciguat activates an enzyme called soluble guanylyl cyclase. It's in a Phase 2b/3 trial (KATALYST-AV) for moderate calcific aortic valve stenosis, a disease where calcium deposits harden and narrow the aortic valve. Right now, the only option for severe cases is surgery. There's nothing approved to slow the progression while it's still moderate.

Tonlamarsen is an antisense oligonucleotide (a short strand of synthetic genetic material that blocks a specific protein) targeting angiotensinogen. It's being studied in a Phase 2b trial called KARDINAL-ASH for acute severe hypertension after hospitalization.

Kardigan plans to allocate roughly $80 to $90 million each to danicamtiv and ataciguat, with $40 to $50 million going to tonlamarsen. Combined with prior fundraising (a $300M Series A and a $254M Series B), the company says it has enough capital to operate into 2028.

Where Kardigan Fits in a Record-Breaking IPO Year

The 2026 biotech IPO market has been unlike anything since 2021. Two companies have already shattered records: Parabilis Medicines raised roughly $670 to $770 million, and Kailera Therapeutics (an obesity-focused company) brought in about $625 million. Both are among the largest biotech IPOs in history, depending on how you count concurrent private placements.

Kardigan's $400 million sits in the next tier, alongside Generate:Biomedicines ($400M), Eikon Therapeutics ($381M), and Aktis Oncology ($365M). It's not the biggest of the year, but it's comfortably in the top five or six. Biopharma companies raised $1.7 billion in IPOs in Q1 alone, with three offerings exceeding $300 million, a pace rarely seen outside the 2021 bubble.

The difference between 2021 and now? Discipline. Analysts describe 2026 as the first "rational funding year" since 2018. Investors are writing big checks, but only for companies with late-stage data, experienced teams, and clear paths to the clinic. Speculative platforms and early-stage science aren't getting the same love.

Why Cardio Is the New Cool Kid

For years, oncology dominated biotech investing. Cancer drugs got the biggest deals, the highest valuations, and most of the attention. That's starting to shift.

Patent cliffs on legacy diabetes and lipid drugs are forcing big pharma to shop aggressively for next-generation assets. PwC's 2026 midyear outlook explicitly names cardiometabolic and obesity among the highest-priority deal areas, right alongside oncology and immunology.

Several analysts now expect capital to rotate toward cardiometabolic and away from oncology's traditional dominance, driven by the enormous market opportunity and a surge of innovation in obesity, NASH/MASH (fatty liver disease), and cardiovascular risk reduction.

Kardigan isn't riding the obesity wave specifically. Its targets are more niche: rare-ish genetic heart diseases and underserved cardiovascular conditions. But the broader investor enthusiasm for all things heart-and-metabolism related clearly helped it price at the top of its range.

The Bottom Line

Kardigan is a fascinating case study in biotech brand equity. A proven team, reuniting after a $13.1 billion exit, building a new company in a therapeutic area with massive unmet need. The IPO market rewarded that story with $400 million (potentially $460 million) in fresh capital.

The risk? All three drugs are still in Phase 2b. None have pivotal data yet. Cardiovascular trials are notoriously expensive, long, and prone to failure. Having the MyoKardia pedigree doesn't guarantee the science works.

But if you're going to bet on a cardiovascular biotech, betting on the team that already won once is about as rational as biotech investing gets. Wall Street clearly agrees.

The FDA Just Carpet-Bombed 25 Telehealth Companies Over Knockoff Ozempic

The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.